Stock Events

Stock Events

Embecta

$9.23

61

-$0.67-6.77% Tuesday 03:37

Statistics

Day High

9.23

Day Low

9.23

52W High

-

52W Low

-

Volume

138

Avg. Volume

-

Mkt Cap

546.6M

P/E Ratio

-

Dividend Yield

6.5%

Dividend

0.6

Upcoming

Dividend Payment

Dividend Payment

Dividends

6.5%Dividend Yield

Mar 26

$0.15

Dec 25

$0.15

Sep 25

$0.15

Jun 25

$0.15

Mar 25

$0.15

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

8MayExpected

Q3 2025

Q4 2025

Next

0.42

0.51

0.61

0.71

Expected EPS

0.4166

Actual EPS

N/A

Financials

8.83%Profit Margin

Profitable

2022

2023

2024

2025

2.16BRevenue

190.8MNet Income

Analyst Ratings

$25.00Average Price Target

The highest estimate is 25.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EMBC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Medtronic is a major player in the medical devices sector, directly competing with Embecta in the diabetes management space, including insulin pumps and glucose monitoring systems.

Abbott Laboratories

Abbott Laboratories offers a wide range of medical devices, diagnostics, and nutritional products, competing with Embecta in areas such as glucose monitoring.

DexCom specializes in continuous glucose monitoring (CGM) systems, a direct competitor to Embecta's diabetes care products.

Tandem Diabetes Care

Tandem Diabetes Care is a direct competitor in the insulin pump market, offering advanced diabetes management systems.

Insulet Corporation specializes in tubeless insulin pump technology, competing in the insulin delivery market alongside Embecta.

Novo Nordisk is a global healthcare company with a strong focus on diabetes care, including insulin and devices, competing with Embecta's offerings.

Sanofi is involved in diabetes care through its insulin and glucose monitoring products, making it a competitor to Embecta.

Bristol-Myers Squibb

Bristol Myers Squibb, through its acquisition of MyoKardia, has expanded into various healthcare sectors, potentially competing with Embecta in the broader medical devices and healthcare market.

Johnson & Johnson

Johnson & Johnson, through its medical devices segment, competes in the healthcare market, including areas that overlap with Embecta's diabetes care products.

Boston Scientific

Boston Scientific Corporation operates in the medical devices sector, competing in various areas that could intersect with Embecta's market, including diabetes care solutions.

About

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Show more...

CEO

ISIN

US29082K1051

Listings

0 Comments

Share your thoughts

FAQ

What is Embecta stock price today?▼

The current price of EMBC.BOATS is $9.23 USD — it has decreased by -6.77% in the past 24 hours. Watch Embecta stock price performance more closely on the chart.

What is Embecta stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Embecta stocks are traded under the ticker EMBC.BOATS.

What is Embecta market cap?▼

Today Embecta has the market capitalization of 546.6M

When is the next Embecta earnings date?▼

Embecta is going to release the next earnings report on May 08, 2026.

What were Embecta earnings last quarter?▼

EMBC.BOATS earnings for the last quarter are 0.71 USD per share, whereas the estimation was 0.67 USD resulting in a +5.81% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Embecta revenue for the last year?▼

Embecta revenue for the last year amounts to 2.16B USD.

What is Embecta net income for the last year?▼

EMBC.BOATS net income for the last year is 190.8M USD.

Does Embecta pay dividends?▼

Yes, EMBC.BOATS dividends are paid quarterly. The last dividend per share was 0.15 USD. As of today, Dividend Yield (FWD)% is 6.5%.

When did Embecta complete a stock split?▼

Embecta has not had any recent stock splits.